The UK life sciences sector remains one of the country’s most valuable economic engines. According to the latest data from the Office for Life Sciences, the industry now comprises more than 6,000 businesses employing around 360,000 people and generating approximately £146.9 billion in annual turnover.
It is also one of the most productive sectors in the economy, with a highly skilled workforce and significant R&D intensity, contributing substantial economic value while supporting high-value jobs across the country.
Yet for all its scientific excellence and economic weight, the sector faces a fundamental constraint: time.
In advanced therapies, time is not an abstract metric. It is investment runway, competitive advantage, patent life, patient outcomes and increasingly, national economic positioning. As the UK seeks to cement its place as a global leader under the Department of Health and Social Care’s innovation strategy, the ability to translate discovery into delivery quickly will define success.
The Infrastructure Bottleneck
The UK has a world-leading academic base and a proven ability to generate high-value IP. What it lacks is sufficient, purpose-built laboratory and GMP manufacturing space to support rapid scale-up.
In Cambridge alone, there is approximately 3.1 million sq. ft of existing lab stock, against a pipeline requirement of 5.3 million sq. ft, with over half of that pipeline still at pre-planning stage. Similar pressures are evident across Oxford and London. Demand continues to outstrip supply, forcing growing biotech and advanced therapy companies to secure space years in advance.
This imbalance creates risk. Scientists and venture capital investors are rightly focused on clinical milestones and scientific progression. Infrastructure planning frequently becomes reactive rather than strategic. The result? Delays of 18–24 months for traditional construction programmes; timelines that are fundamentally misaligned with the pace of modern biotech.
For cell and gene therapy developers, waiting two years for a facility can mean missed trial windows, lost talent and reduced investor confidence.
Why Speed to Market Is Strategic
Speed to market in life sciences real estate is not simply about convenience. It is a strategic decision with direct implications for competitiveness and revenue potential.
The global biotechnology market is forecast to reach $1.6 trillion by 2030, driving significant demand for biopharma cleanroom and advanced manufacturing space. Countries that can provide the right infrastructure at the right pace will capture a disproportionate share of that growth.
Accelerating time to operational readiness also directly supports drug development timelines. The planning, design, manufacture, assembly and validation of facilities must align with original equipment manufacturer lead times. An ambitious but necessary benchmark for many projects is 12 months or less from concept to validated facility.
Traditional construction methodologies struggle to meet this requirement. Fragmented supply chains and variable site conditions introduce delay and uncertainty – precisely the risks life sciences organisations can’t afford.
Industrialising Construction for Industrial-Scale Science
Offsite manufacturing offers a fundamentally different approach.
By shifting complex construction activities into controlled factory environments, modular construction enables parallel working, precision engineering and rigorous quality assurance. Components are manufactured while groundworks and enabling works progress on site. This compresses programme durations and reduces exposure to weather, labour shortages and supply chain volatility.
For highly regulated environments such as GMP cleanrooms, the benefits are particularly compelling. Digital manufacturing techniques allow best practice to be embedded into repeatable product platforms. Greater time and resource are invested upfront in resolving complex interfaces and compliance requirements, simplifying application at project level. The result is a process-centric design approach that supports optimal equipment layout and workflow configuration.
Manufacturing in purpose-built facilities also drives productivity gains, improves quality consistency and reduces waste. Compared to traditional site construction, factory-based production significantly lowers material waste and carbon footprint.
As our CEO, Tony Wells, states: “Offsite manufacturing brings enormous advantages in speed, quality and sustainability — all of which are critical for biotech and pharma. The time taken to plan, design, manufacture, assemble and validate a facility must match the pace of the science itself.”
This approach is about more than faster buildings. It is about protecting competitive position, accelerating patient access to therapies and supporting the UK’s ambition to lead globally.
Looking Ahead to 2026 and Beyond
The UK has the opportunity to establish itself as the pre-eminent global hub for advanced therapies and biotech innovation. Achieving this requires pace over perfection: increased R&D funding, enhanced clinical trials infrastructure, a strong talent pipeline and critically, rapid delivery of high-quality, future-ready facilities.
In advanced therapies, time is the real currency.
If we want the UK to remain at the forefront of cutting-edge science, delivering health, wealth and prosperity, our infrastructure must move at the speed of innovation.
